Clinical evaluation on Orion GenRead RSV test is now published -

Käytämme sivustoillamme evästeitä sivuston toimivuuden varmistamiseksi ja mahdollistaaksemme parhaan käyttökokemuksen.
Jatkamalla sivuston käyttöä hyväksyt evästeet. Lue lisää evästeistä täältä.

You appear to be from the USA. Would like to proceed to Products available in the USA?

Clinical evaluation on Orion GenRead® RSV test is now published

The preliminary clinical evaluation on Orion GenRead® RSV – respiratory syncytial virus – is now available. Orion GenRead RSV utilizes the RT-SIBA isothermal nucleic acid amplification technology.  A total of 142 (85 RSV positive and 57 RSV negative) nasopharyngeal swab specimens were evaluated. The sensitivity and specifity of Orion GenRead RSV were 99% and 100% respectively. The RSV positive specimens were available within 15 minutes. The evaluation concludes that the new Orion GenRead RSV test provides combination of simple sample preparation with fast detection of RSV and hence the test can be used in decentralized settings to facilitate fast diagnosis of RSV infection.

RSV is a major cause of respiratory tract infections, especially among pediatric, elderly and immunocompromised patients. The virus in responsible for over 60% of acute respiratory tract infections and is the most common cause of bronchiolitis and pneumonia in young children.

Orion GenRead RSV test will be commercially available later in 2018.